Description Module

Description Module

The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.

Description Module path is as follows:

Study -> Protocol Section -> Description Module

Description Module


Ignite Creation Date: 2025-12-26 @ 10:58 AM
Ignite Modification Date: 2025-12-26 @ 10:58 AM
NCT ID: NCT05715008
Brief Summary: The purpose of this study is to examine the effect of kefir consumption on anthropometric, physiological and redox status parameters in adult subjects, and compare it with the intake of placebo drink (milk).
Detailed Description: Importance of the research Several chronic diseases are related with alterations in redox status. Over the years several nutritional approaches have been implemented in order to examine modulation of the redox status. Kefir is a product that can alter the gut microbiome and potentially affect the redox status. This study will help elucidate whether the consumption of a dairy product (kefir) will modulate anthropometric, physiological and oxidative stress parameters. Methodology 1. Sample: The study will involve 16 adult volunteers, (8-experimental group and 8-control group), aged 20-60 years. The subjects will participate in a double-blind, randomized study, where in one condition they will receive kefir (300 ml per day - 150 ml in the morning and 150 ml in the evening) and in the next condition they will receive regular cow milk as a placebo. 2. Process of collecting results: At first visit of volunteers to the laboratory, anthropometric (height, weight, body fat percentage, waist and hip circumferences) and physiological measurements (heart rate, blood pressure) will be taken. Volunteers will also be given full instructions on how to record their diet. They will be given a form to record their diet for 3 days and will have to follow the same date before each next visit to the laboratory. Then they will have their second visit to the laboratory, where the first blood sampling will be taken, and they will be given the necessary amount of kefir or placebo (depending on the group to which they belong), which they will have to consume as a supplement for the following two weeks. At the end of the 2 weeks the volunteer will return to the laboratory where the second blood sampling will be performed. This will be followed by a 2-week washout period where participants will not receive any amount of kefir or placebo. At the end of this intervention, a fourth visit to the laboratory will take place, where the third blood sampling will be performed. Subsequently, the consumption of kefir or placebo will continue, except that participants who initially consumed kefir will receive the placebo and vice versa. The last blood sampling (fourth) will take place after two weeks. 3. Measuring instruments: Dual-energy X-ray absorptiometry (DEXA) and a mechanical balance with a stadiometer will be used to determine the anthropometric characteristics. A Gulick tape measure will be used to measure the waist and hip circumferences. For the measurement of heart rate a polar type heart rate monitor will be used. A sphygmomanometer will be used to measure blood pressure. The dietary characteristics of their diet will be analysed using a Science Fit Diet 200A (ScienceFit, Greece). Parameters in the blood will be analyzed by Immunoenzymatic Analysis (ELISA) and visible-ultraviolet spectrophotometer. 4. Blood parameters: A portion of the blood will be utilized for a complete blood count analysis and parameters related to redox status (protein carbonyls, thiobarbituric acid reactive substances, reduced glutathione, oxidized glutathione, catalase, total antioxidant capacity, uric acid). Statistical Analysis A 2-way ANOVA with repeated measures will be performed. The statistical program SPSS 26 will be used.
Study: NCT05715008
Study Brief:
Protocol Section: NCT05715008